Daniel J. Abrams, M.D., CEO
Dr. Abrams is a cofounder of Cerebral Therapeutics and serves as the Company’s Chief Executive Officer. Prior to founding Cerebral Therapeutics, Dr. Abrams founded Sierra Neuropharmaceuticals, Inc., raising $21.5 million in Series A venture capital. Dr. Abrams has practiced clinically both as a neurosurgeon and a psychiatrist and served as head of the Department of Neurosurgery at St. Joseph’s Hospital in Denver. Dr. Abrams’ practical clinical experience with implantable pumps and neurologically active medications, along with his experience in pharmaceutic drug development, make him well matched to lead Cerebral Therapeutics in its focus of brain drug delivery.
Warren Lammert, Director - Founder and Chief Investment Officer of Granite Point Capital
Mr. Lammert is Founder, Principal and Chief Investment Officer of Granite Point Capital, which was formed in January 2004. He is also the former Chair of the Epilepsy Foundation, which he joined in 2013 following its merger with the Epilepsy Therapy Project, an organization that Mr. Lammert co-founded and chaired. Prior to the formation of Granite Point Capital, Mr. Lammert spent 14 years at Janus serving in several investment and senior management roles from its inception in 1993 until March 2003. From 1984 to 1987, Mr. Lammert served in equity research roles at Fred Alger Management.
Mahendra G. Shah, Ph.D., Director - Managing Director of Vivo Capital
Dr. Shah is a highly successful pharmaceutical entrepreneur and executive who has been at Vivo Capital since March 2010. He is also the Founder and Executive Chairman of Semnur Pharmaceuticals. Dr. Shah currently serves as Chairman of the Board of Essentialis Therapeutics, board member of Biotie Therapies (NASDAQ: BITI), and a member of the Board of Trustees of St. John’s University. From 2005 to 2009, Dr. Shah was the Founder, Chairman and CEO of NextWave Pharmaceuticals, which was sold to Pfizer for $700 million in upfront and milestone payments. From 1993 to 2003 he was Chairman and CEO of First Horizon Pharmaceuticals, where he raised > $200 million and built a highly profitable company before it was sold to Shionogi Pharmaceuticals for $1.4 billion. From 1991 to 1999, he was Vice President of E. J. Financial Enterprises, Inc. Previously Dr. Shah served on the Boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics (INGN), Inpharmakon, Protomed, Structural Bioinformatics, and Zarix. From 1987 to 1991 he was the Senior Director of New Business Development at Fujisawa USA (Astellas) and previously he worked in various scientific and management positions at Schering-Plough and Bristol Myers-Squibb.
Stephen J. Farr, Ph.D., Director - Co-Founder, President and CEO of Zogenix, Inc.
Dr. Farr has been President and Chief Executive Officer of Zogenix (NASDAQ: ZGNX) since April 2015, where he served as President and Chief Operating Officer since the company’s founding in 2006. Previously, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006, serving most recently as Senior Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, UK, concentrating in the areas of biopharmaceutics. Dr. Farr is a Director on the Board of SteadyMed (NASDAQ: STDY) and two private companies, Oscillari, LLC, and Flow Pharma, Inc. He is author/co-author of > 180 scientific publications and patents and retains his academic interests as adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA.
Ashwini Sharan, M.D., Senior Medical and Scientific Advisor
Professor Sharan is the Surgical Director of the Epilepsy Center and the Residency Program Directory at Jefferson University. In addition, Dr. Sharan is the President of the North American Neuromodulation Society and the Congress of Neurological Surgeons. Dr. Sharan is one of the leaders who developed the field of Neuromodulation as a leading area in Neurological Surgery. Dr. Sharan is the author of numerous papers, holds multiple patents and serves as an international physician leader in new therapy development, education, and patient advocacy.
Robert Fisher, MD Senior Scientific and Medical Adviser
Dr. Fisher is Maslah Saul MD Professor and Director of the Stanford Epilepsy Center. He had research awards from the Klingenstein Foundation, EF, CURE and NIH. He has published 160 peer-reviewed articles and 4 books. He was named 1996-2016 in Best Doctors in America. He received the Ambassador Award from the International League Against Epilepsy, the 2005 AES Service Award and the 2006 Annual Clinical Research Award. Dr. Fisher is Past-President of the American Epilepsy Society, and has served on the Board of the ILAE and as Editor-in-Chief of the Journal, Epilepsia. He is past Editor-in-Chief of the website epilepsy.com.